The approval of ursodeoxycholic acid (UDCA) for primary biliary cholangitis (PBC) in 1997 marked a pivotal turning point in ...

Advanz won a temporary reprieve in September after the General Court of the European Union ordered a suspension of the EC's ...

Ipsen has shared positive three-year results for Iqirvo (elafibranor) in patients with the rare cholestatic liver disease ...

As the largest internal organ in the human body, the liver supports a wide range of responsibilities related to metabolism, ...

Ipsen has been given accelerated approval by the FDA for Iqirvo, which becomes the first dual PPAR alpha/delta agonist for rare cholestatic liver disease primary biliary cholangitis (PBC).

This latest update comes after Advanz secured a suspension of the European Commission’s original revocation in September 2024 ...

MIRM's lead drug, Livmarli, is driving revenues and the momentum is likely to continue. The company's efforts to build its pipeline beyond Livmarli also hold promise.

GILD has put up a solid performance in the past six months on positive data readouts and strong quarterly results. We believe ...

A fundraiser has been set up for a University of South Wales graduate who’s been diagnosed with a rare and aggressive cancer ...

According to the NHS, most types of liver disease don't cause any symptoms in the early stages. Therefore, it means that once ...

The conditional marketing approval for Ocaliva (obeticholic acid) has been revoked with immediate effect, following a standoff between the EMA and Advanz Pharma Ltd., the company that markets the ...

UK-based drugmaker Advanz Pharma has announced that following the grant of a temporary suspension, as announced on last month ...